Myogen Inc Myriad Entertainment & Resorts Inc Myriad Genetics Inc N
Total Page:16
File Type:pdf, Size:1020Kb
THE CORPORATE DIRECTORY - Walker's 2007 Nabors Industries Ltd - 1113 prevention of major diseases. The predictive medicine segment provides testing to determine Myogen Inc predisposition to common diseases. The group has made discoveries in the fields of cancer, viral diseases such as aids and acute thrombosis. It hasalliances with 12 major multinational companies including abbott 7575 West 103rd Ave, Ste 102, Westminster, CO, 80021; PH: 1-303-410-6666; laboratories, bayer corporation, e.i. Du pont de nemours and company (dupont), eli lilly and company, Fax: 1-303-410-6667; http:// www.myogen.com; Email: [email protected] hitachi ltd, hoffmann-laroche inc, novartis corporation, oracle corporation, pharmacia corporation, General - Incorporation.............................. DE Stock- Price on:12/22/2006 .....................$64.5 schering ag, schering-plough corporation and torrey mesa research institute. Employees ....................................................1,900 Stock Exchange............................................NDQ Primary SIC and add’l.: 8731 2834 Auditor ................................. Ernst & Young LLP Ticker Symbol.............................................GILD CIK No: 0000899923 Stk Agt.............................................................NA Outstanding Shares ...........................459,830,000 Myriad Financial, Inc., Myriad Genetic Laboratories, Inc., Myriad Counsel.............................. Cooley Godward LLP E.P.S.............................................................$1.58 Subsidiaries: Pharmaceuticals, Inc. DUNS No. .......................................................NA Shareholders....................................................290 Catherine Oyler/Dir. - Business Development Predictive Medicine, Patrick Burke/Dir. - The group’s principalactivity is to develop and commercialize smallmoleculetherapeutics Officers: Business: Business Development Therapeutics, James S. Evans/VP - Finance, Myriad Genetics, Inc, Jerry for the treatment of cardiovascular disorders. It has three product candidates in late-stage clinical Lanchbury/Exec. VP - Research - Myriad Genetics, Inc, Richard Marsh/Exec. VP, General Counsel, development: enoximone capsules for the treatment of chronic heart failure, ambrisentan for the treatment Sec. - Myriad Genetics, Inc, William A. Hockett/Exec. VP - Corporate Communications - Myriad of pulmonary arterial hypertension and darusentan for the treatment of uncontrolled hypertension. In Genetics, Inc, Peter D. Meldrum/Dir., Pres., CEO - Myriad Genetics, Inc/$615,475.00, Mark H. addition, the group currently markets an intravenous formulation of enoximone, perfan i.v. For the Skolnick/Dir., Chief Scientific Officer - Myriad Genetics, Inc/$342,043.00, George S. Simon/Exec. treatment of acute decompensated heart failure in eight countries in Europe. The group operates in the VP - Business Development - Myriad Genetics, Inc, Jay M. Moyes/CFO - Myriad Genetics, United States and in certain countries throughout Europe. Inc/$326,975.00 Primary SIC and add’l.: 2834 8731 Directors: Dennis Langer/Dir., Arthur H. Hayes/Dir., Walter Gilbert/Dir., Vice Chmn., MD - CIK No: 0001101052 Bioventures Investors, Robert S. Attiyeh/Dir., John T. Henderson/Chmn., Peter D. Meldrum/Dir., Subsidiaries: Myogen GmbH Pres., CEO - Myriad Genetics, Inc, Mark H. Skolnick/Dir., Chief Scientific Officer - Myriad Genetics, Officers: William J. Freytag/Chmn. - Board, Dir., Pres., CEO/$357,000.00, Andrew D. Inc, Linda S. Wilson/Dir. Dickinson/37/VP - Corporate Development, General Counsel, Sec., Derek Cole/Dir. - Investor Owners: LindaS.Wilson,WalterGilbert,PeterD.Meldrum/1.80%,ArthurH.Hayes,T.Rowe Relations, Myogen, Inc, Robert Caspari/Sr. VP - Commercial Operations, Medical Affairs, Joseph L. Price Associates, Inc./10.00%, Gregory C. Critchfield/1.10%, Dennis H. Langer, Jay M. Turner/Sr. VP - Finance, CFO, Treasurer, Assist. Sec./$227,000.00, Michael J. Gerber/Sr. VP - Moyes/1.10%, FMR Corp./9.70%, Adrian N. Hobden/1.50%, Platinum Asset Management, Clinical Development, Regulatory Affairs/$271,300.00, Richard J. Gorczynski/Sr. VP - Research, Ltd./5.00%, John T. Henderson, Mark H. Skolnick/2.60%, Robert S. Attiyeh Development/$240,700.00, John R. Julian/Sr. VP - Commercial Development/$246,800.00 Financial Data: Fiscal Year End:06/30 Latest Annual Data: 06/30/2006 Directors: William J. Freytag/Chmn. - Board, Dir., Pres., CEO, Daniel J. Mitchell/Dir., Member - Year Sales Net Income Audit Committee, Chairperson - Compensation Committee, Kirk Calhoun/Dir., Chairperson - Audit 2006 $114,279,000 -$38,189,000 Committee, Judith A. Hemberger/Dir., Member - Compensation Committee, Arnold L. Oronsky/Dir., 2005 $82,406,000 -$39,978,000 Member - Audit Committee, Nominating, Corporate Governance Committee, Michael J. 2004 $56,648,000 -$40,620,000 Valentino/Dir., Member - Compensation Committee, Jerry T. Jackson/Dir., Chairperson - Curr. Assets: $252,287,000 Curr. Liab.: $26,822,000 Nominating, Corporate Governance Committee, Michael R. Bristow/Dir., Sigrid V. Bladel/Dir. - Plant, Equip.: $19,829,000 Total Liab.: $26,822,000 Indic. Yr. Divd.: NA Nominating, Corporate Governance Committee Total Assets: $276,603,000 Net Worth: $249,781,000 Debt/ Equity: NA Owners: Daniel J. Mitchell/2.06%, Michael J. Gerber, Joseph L. Turner, Kirk K. Calhoun, Michael J. Valentino, John R. Julian, Arnold L. Oronsky/2.25%, Jerry T. Jackson, William J. Freytag/2.05%, S.A.C. Capital Advisors, LLC/5.84%, Michael R. Bristow, Richard J. Gorczynski, Sigrid Van Bladel, T. Rowe Price Associates, Inc./8.42% N Viro International Corp Financial Data: Fiscal Year End:12/31 Latest Annual Data: 12/31/2005 3450 W Central Ave, Ste 328, Toledo, OH, 43606; PH: 1-419-535-6374; Fax: 1-419-535-7008; Year Sales Net Income http:// www.nviro.com; Email: [email protected] 2005 $2,028,400,000 $813,914,000 General - Incorporation ............................. DE Stock- Price on:12/22/2006 .....................$2.09 2004 $1,324,621,000 $449,371,000 Employees .........................................................11 Stock Exchange.............................................OTC 2003 $867,864,000 -$72,003,000 Auditor .................................................UHY LLP Ticker Symbol...................................... NVIC.OB Curr. Assets: $3,092,208,000 Curr. Liab.: $455,338,000 Stk Agt.............................................................NA Outstanding Shares ...............................3,730,000 Plant, Equip.: $242,568,000 Total Liab.: $736,873,000 Indic. Yr. Divd.: NA Counsel............................................................NA E.P.S........................................................... -$0.07 Total Assets: $3,764,651,000 Net Worth: $3,027,778,000 Debt/ Equity: 0.3940 DUNS No. ........................................ 80-856-3332 Shareholders....................................................190 Business: The group’s principal activity is to own and license the n-viro process. The n-viro process is a patented process for the treatment and recycling of bio-organic wastes, utilizing certain alkaline Myriad Entertainment & Resorts Inc by-products produced by the cement, lime, electric utilities and other industries. The group operates through four segments: management operations, other domestic operations, foreign operations and 10050-112 St, Ste 1000, 10th Floor, Edmonton, AB, T5K 2J1; PH: 1-780-431-0086; research and development. The management operations segment provides employee and management Fax: 1-780-447-2981; http:// www.myriadgolf.com; Email: [email protected] services to operate the toledo wastewater treatmentfacility. The domestic and foreign operationssegments General - Incorporation.............................. DE Stock- Price on:12/22/2006 .......................$0.3 license the use of n-viro technology. The research and development segment contracts with federal and Employees ...........................................................1 Stock Exchange.............................................OTC state agencies to perform research and development on the company’s technology. The group operates Auditor .............................. Moore Stephens Frost Ticker Symbol....................................MYRA.OB solely in the domestic market. Stk Agt........................... Securities Transfer Corp Outstanding Shares .............................43,460,000 Primary SIC and add’l.: 9511 8731 6794 Counsel............................................................NA E.P.S............................................................. -$0.1 CIK No: 0000904896 DUNS No. .......................................................NA Shareholders....................................................442 Subsidiaries: American N-Viro Resources, Inc., BioCheck Laboratories, Inc., Midwest N-Viro, Business: The group’s principal activities are to provide information technology and organizational Inc., N-Viro Honolulu, Inc., National N-Viro Tech., Inc., Pan-American N-Viro, Inc., management products and services. It offers a suite of products and services for solving systems problems Tennessee-Carolina N-Viro, Inc., Viro Soil South, Inc. related to their rapidly changing technology needs. The group also provides management consulting James K. Mchugh/48/CFO, Sec., Treasurer, Timothy R. Kasmoch/45/Dir., CEO, Pres., services for project management, organizationaland workforce issues related to company reorganizations, Officers: Howard E. Hartung/37/COO, Cindy Drill/Product Mgr. - Great Lakes Division, Tim mergers and acquisitions.